Contact Us: 1-888-667-3325 / customerservice@thedeal.com

Subscriber Content Preview | Request a free trialSearch  
  Go

Entries tagged "Private Equity"

You have executed a tag search on The Deal Pipeline. Below, you will find a comprehensive list of stories tagged "Private Equity."

12 result(s) displayed (73 - 84 of 624)


This video is exclusive to The Deal Pipeline

M&A Outlook for 2013

Paul, Weiss partner Ariel Deckelbaum talks to The Deal about the forces driving M&A in 2013 including the E.U., activist investors, corporate acquirers and private equity.
Posted on January 4, 2013 11:43 AM



EMPEA's Sarah Alexander on PE in emerging markets

The CEO of the Emerging Markets Private Equity Association discusses areas of the world such as Latin American and Africa where LBO are getting active. Continue reading

Posted on December 21, 2012 2:46 PM




Oracle acquires Eloqua for $871M

Deal continues the buyer's push to add cloud-computing software through acquisitions. Continue reading

Posted on December 20, 2012 12:09 PM




Best Buy extends bid deadline

Richard Schulze will examine Christmas sales and year-end financials before making an offer. Continue reading

Posted on December 14, 2012 11:39 AM




KKR's Ken Mehlman on the fiscal cliff and 2013 outlook

The Global Head of Public Affairs at Kohlberg Kravis Roberts & Co. talks about the fiscal cliff at The Deal Economy 2013 conference. Continue reading

Posted on December 12, 2012 4:16 PM




EMPEA's Sarah Alexander on PE and emerging markets

Sarah Alexander, the President and CEO of the Emerging Markets Private Equity Association (EMPEA) spoke at The Deal Economy 2013 conference on the role that the buyout industry is playing in emerging markets in Asia and Africa. Continue reading

Posted on December 10, 2012 4:52 PM




KKR's Jamie Weinstein on European debt funding markets

The co-head of Special Situations at KKR Asset Management spoke about the availability of debt financing in the European Union at The Deal Economy 2013. Continue reading

Posted on December 4, 2012 2:54 PM




Prospect Capital Advisor's Leslie Hardin on PE fundraising

The founder and managing partner of Prospect Capital Advisors discusses the reputation of the buyout industry in a post-election environment, as well as the the landscape of fundraising for LBO vehicles at the 2012 Yale Private Equity conference. Continue reading

Posted on November 26, 2012 2:19 PM




Wilbur Ross on PE, dividend recaps and leverage levels

The chairman and chief executive of WL Ross & Co. discuss debt levels on buyouts, dividend recaps and the possibility of another financing bubble similar to the one created between 2005 and 2007. Continue reading

Posted on November 13, 2012 3:24 PM




CD&R's Joseph Rice on carried interest and the future of PE

One of PE's founding fathers speaks to The Deal Pipeline about the ways that presidential election may affect LBO deals, as well as the tax treatment of carried interest. Continue reading

Posted on November 12, 2012 2:29 PM




GTCR's David Katz on PE, Obamacare & Romney's campaign

GTCR's David Katz speaks with The Deal Pipeline's Taina Rosa at the Yale Private Equity conference about the effect of Mitt Romney's campaign on the LBO industry. Continue reading

Posted on November 9, 2012 2:37 PM




Milestone's Nowaczyk on middle-market dealmaking

Milestone Partners' John Nowaczyk discusses the firm's portfolio company Martex Fiber and manufacturing opportunities coming back to the U.S. Continue reading

Posted on October 24, 2012 10:22 AM




Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next

Movable Type search results powered by Fast Search



Popular tags




Movers & Shakers

Launch Movers and shakers slideshow

Rothschild's James Friel will join Renaissance Capital as global head of investment banking, strengthening his ties with Russian billionaire and Nets owner Mikhail Prokhorov. For other updates launch today's Movers & shakers slideshow.

Video

Teva springs for $40.5B Allergan Generics acquisition

Teva Pharmaceutical will acquire the generics business of Botox maker Allergan and subsequently abandon a $40 billion, hostile pursuit for its peer Mylan. More video

Sectors